Industry M&A Weekly: Lilly's $3.8B AtaiBeckley Bet, Tempus-Personalis, and Two More

Eli Lilly's agreement to buy AtaiBeckley for an initial $2.8 billion, with as much as $1.0 billion more in contingent value, was the week's largest newly disclosed transaction. Three other deals followed in biotech and adjacent platforms: Tempus agreed to buy cancer-testing company Personalis for $1.5 billion, Samsung Biologics launched a CHF1.46 billion tender offer for peptide CDMO PolyPeptide, and Jupiter Neurosciences licensed U.S. rights to PharmAla's ALA-002 for up to $100 million.

Lilly will acquire all outstanding AtaiBeckley shares for $6.75 in cash at closing, or about $2.8 billion of equity value. Shareholders can receive up to another $2.50 per share through contingent value rights tied to development and regulatory milestones, taking the potential total to about $3.8 billion. The agreement was announced on July 16 and is expected to close in the third quarter, subject to shareholder and other regulatory approvals. 1 2

AtaiBeckley is a clinical-stage mental-health biotech. Its lead program, BPL-003, is an intranasal form of mebufotenin benzoate, a synthetic form of 5-MeO-DMT, being developed for treatment-resistant depression. The pipeline also includes a buccal DMT film, VLS-01, and an (R)-MDMA program for social anxiety disorder. Lilly said the acquisition expands its neuroscience pipeline and brings programs that may work through mechanisms distinct from conventional antidepressants. 2 9

The structure leaves part of the purchase price dependent on clinical and regulatory progress. That lowers Lilly's upfront exposure while giving AtaiBeckley shareholders a path to a higher outcome if BPL-003 and the wider pipeline deliver.

Tempus agreed on July 20 to acquire Personalis for about $1.5 billion of enterprise value, at $16.25 per share. The consideration is primarily stock, with Tempus able to elect cash for up to half of the deal; the companies expect to close in late 2026 or early 2027 after shareholder and regulatory approvals. 3 4

Personalis develops advanced genomic tests for precision oncology. Its NeXT Personal test is a tumor-informed molecular residual disease, or MRD, assay: it uses a patient's tumor sample to look for tiny amounts of cancer left after treatment and to detect recurrence earlier. Personalis reported preliminary second-quarter revenue of $22.4 million and 10,384 tests, up 33% from the prior quarter. 3

Tempus already had a co-commercialization relationship with Personalis dating to 2023. The stated rationale is to link Personalis' tumor-informed testing with Tempus' AI, multimodal data, and commercial reach, covering more of the cancer-care cycle from diagnosis and treatment selection through recurrence monitoring. The deal is a platform-integration move as much as a product acquisition. 4

Samsung Biologics launched an all-cash tender offer for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares. The offer is CHF44.31 per share, implying an equity value of about CHF1.46 billion, or roughly $1.8 billion. Samsung said the offer is expected to launch by the end of August, with completion toward the end of 2026 if the 66⅔% minimum acceptance threshold and regulatory conditions are met. 5

PolyPeptide is a Switzerland-based contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients. It has more than 70 years of manufacturing history, has produced over 1,000 therapeutic peptides, and operates sites in Sweden, Belgium, France, the United States, and India. 5

The rationale is direct. Samsung wants to move beyond antibodies and antibody-drug conjugates into peptides, a modality whose commercial profile has been reshaped by GLP-1 medicines. PolyPeptide supplies specialized process know-how and a global manufacturing footprint; Samsung supplies scale and a broader end-to-end CDMO network. 5 6

Jupiter Neurosciences signed a definitive agreement on July 21 for exclusive, perpetual, sublicensable U.S. rights to ALA-002, PharmAla's lead candidate. The deal carries $3.33 million in upfront consideration, split between cash and Jupiter stock, plus up to $96.67 million in development, regulatory, and commercial milestones. Royalties on U.S. net sales are separate, so the stated transaction value is up to $100 million before royalties. 7 8

ALA-002 is a patented non-racemic MDMA formulation with FDA New Chemical Entity designation. PharmAla says the design aims to improve cardiovascular safety and reduce abuse potential while retaining MDMA-assisted-therapy properties. The compound remains investigational and is not approved by the FDA. 8

Jupiter described the license as a way to become a two-asset clinical-stage CNS company alongside its Parkinson's disease program, JOTROL. The economics put most of the risk after the upfront payment: $23.33 million of the milestones are tied to development and FDA approval, while $73.33 million depends on U.S. sales thresholds, followed by a 3% royalty after the third commercial milestone. 7

Each buyer is filling a specific capability gap. Lilly gets psychedelic and nontraditional neuroscience programs; Tempus adds a tumor-informed MRD assay to its AI-enabled oncology platform; Samsung gains peptide manufacturing; and Jupiter adds a second clinical-stage CNS asset. The common thread is specialization rather than broad corporate scale.

Three of the four structures make future performance part of the economics. Lilly uses CVRs, Jupiter uses development, regulatory, and sales milestones plus royalties, and Tempus can choose a mix of stock and cash. Samsung's tender offer is the cleanest cash transaction, but its 66⅔% acceptance threshold and regulatory conditions still leave completion risk. 1 4 5 7

The buyers are bringing different forms of leverage to each target: Lilly's development and commercialization scale, Tempus' data and clinical-sales infrastructure, Samsung's global manufacturing network, and Jupiter's U.S. development path. In each case, the target contributes a specialized asset; the buyer's platform determines how far that asset can travel.

This week's four transactions with disclosed economics were all in biotech or biotech-adjacent diagnostics and manufacturing. No newly disclosed SaaS or fintech transaction with a defensible value was added to the count, so the issue stays concentrated rather than filling the table with a low-confidence deal.